Intech Investment Management LLC Purchases 6,306 Shares of AtriCure, Inc. (NASDAQ:ATRC)

Intech Investment Management LLC raised its position in AtriCure, Inc. (NASDAQ:ATRC) by 41.4% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 21,520 shares of the medical device company’s stock after buying an additional 6,306 shares during the quarter. Intech Investment Management LLC’s holdings in AtriCure were worth $658,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Raymond James Financial Inc. bought a new position in AtriCure in the fourth quarter valued at approximately $3,716,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in shares of AtriCure by 31.5% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,649 shares of the medical device company’s stock worth $14,038,000 after buying an additional 119,929 shares in the last quarter. Two Sigma Advisers LP lifted its position in shares of AtriCure by 14.6% during the 3rd quarter. Two Sigma Advisers LP now owns 664,100 shares of the medical device company’s stock worth $18,621,000 after buying an additional 84,700 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in AtriCure in the third quarter valued at about $1,991,000. Finally, State Street Corp grew its position in AtriCure by 4.9% in the third quarter. State Street Corp now owns 1,344,856 shares of the medical device company’s stock valued at $37,710,000 after acquiring an additional 63,002 shares during the last quarter. 99.11% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other AtriCure news, Director Karen Prange sold 6,100 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the transaction, the director now owns 17,828 shares in the company, valued at approximately $679,603.36. This trade represents a 25.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 3.20% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ATRC shares. Stifel Nicolaus increased their target price on shares of AtriCure from $36.00 to $48.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. JPMorgan Chase & Co. raised their target price on shares of AtriCure from $40.00 to $51.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. JMP Securities reiterated a “market outperform” rating and set a $60.00 price target on shares of AtriCure in a report on Monday, February 10th. Canaccord Genuity Group raised their price objective on AtriCure from $61.00 to $66.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Finally, Piper Sandler boosted their price objective on AtriCure from $40.00 to $50.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $51.56.

AtriCure Trading Down 3.7 %

NASDAQ ATRC opened at $33.54 on Monday. The firm has a market capitalization of $1.64 billion, a PE ratio of -35.30 and a beta of 1.53. The business’s 50-day moving average price is $38.22 and its two-hundred day moving average price is $33.77. The company has a current ratio of 3.65, a quick ratio of 2.62 and a debt-to-equity ratio of 0.13. AtriCure, Inc. has a 12 month low of $18.94 and a 12 month high of $43.11.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.